Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

(2022) Marthe Kirkesæther Brun et al.   JOURNAL OF INTERNAL MEDICINE

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication

(2022) Yutaka Kawahito et al.   Modern Rheumatology

Phase II / III results of the anti‐TNF multivalent NANOBODY ® compound ‘ozoralizumab’ in patient with rheumatoid arthritis ( OHZORA trial)

(2022) Tsutomu Takeuchi et al.   Arthritis & Rheumatology

Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)

(2022) Yoshiya Tanaka et al.   Modern Rheumatology

Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)

(2022) Yoshiya Tanaka et al.   Modern Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

(2022) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   Arthritis & Rheumatology

Exposure‐Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients with Rheumatoid Arthritis

(2020) Stéphane Paul et al.   CTS-Clinical and Translational Science

Rheumatoid arthritis

(2018) Josef S. Smolen et al.   Nature Reviews Disease Primers

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?

(2017) Fowzia Ibrahim et al.   RHEUMATOLOGY

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

(2014) Hideto Kameda et al.   Modern Rheumatology

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES